Study Summary
To investigate the safety and efficacy of CAR-T/CAR-NK cells in patients with recurrent or unresectable solid tumors, including pancreatic cancer, prostate cancer, breast cancer, glioma, etc
Want to learn more about this trial?
Request More InfoInterventions
CAR-T/CAR-NK cell injectionBIOLOGICAL
One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Shandong Province | Jinan | Shandong | China |